Multiple studies, including the MAGIC consortium, HIT2000, and the UK research cohort, have demonstrated that metastatic Group 3 medulloblastoma patients exhibit a poor prognosis, particularly those with MYC amplification. This evidence concerns the gene MYC and medulloblastoma.